Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II
Status:
Recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
To access the anti-tumor efficacy, safety and tolerability of Sunvozertinib combined with
chemotherapy in patients with locally advanced or metastatic non-small-cell lung cancer
(NSCLC) harboring epidermal growth factor receptor (EGFR) sensitizing mutations who have
progressed following standard TKI therapy.